Thank you for attending THSNA 2026. The virtual meeting is now closed.
Use this page to browse all contributing authors.
Presentations for Adam Giermasz
Subcutaneous Four-Week Dosing of the Novel Protein S Antibody VGA039 Demonstrates Safety and Clinically Meaningful Bleed Reduction in Patients with Von Willebrand Disease: Phase 1/2 Multi-Dose Study Results |
Healthcare Resource Utilization in People with Hemophilia Treated Within vs. External to U.S. Hemophilia Treatment Center Network Clinics: An Update from the CHESS US Study |